Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET
**Dosage and Administration** Adult:Oral, 1 to 2 tablets three to four times daily up to a maximum of 8 tablets per day.Children:Not recommended in children. Note: The information given here is limited. For further information consult your doctor or pharmacist.
ORAL
Medical Information
**Indications** Tension headache, occipital headaches associated with spasm of skeletal muscles in the region of the head and neck. Acute and traumatic conditions of the limbs and trunk: sprains, strains, whiplash injuries, acute torticollis, prolapsed intervertebral disc.
**Contraindications** Orphenadrine shows some anticholinergic activity and should not be used in patients with glaucoma, prostatic hypertrophy or obstruction at the bladder neck, or myasthenia gravis.
M03BC51
orphenadrine, combinations
Manufacturer Information
GOLDPLUS UNIVERSAL PTE LTD
Hovid Berhad
Active Ingredients
Documents
Package Inserts
Horgesic Tablet PI.pdf
Approved: January 7, 2022